Vir Biotechnology: Norgine Partnership Extends Cash Runway and De-Risks HDV Franchise, Supporting Buy Rating and $15 Target
at www.tipranks.com (Tue, 30-Dec 6:15 AM)
Vir Biotechnology’s Phase 2 Data Show 66% of CHD Patients Achieve Undetectable HDV RNA with Tobevibart and Elebsiran
Market Chameleon (Mon, 10-Nov 8:41 AM)
